相似文献
1
Addressing the challenges of the clinical application of pharmacogenetic testing.
Clin Pharmacol Ther. 2009 Jul;86(1):28-31. doi: 10.1038/clpt.2009.30.
2
Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories.
Genet Test Mol Biomarkers. 2010 Feb;14(1):121-5. doi: 10.1089/gtmb.2009.0156.
3
Pharmacogenetics: from discovery to patient care.
Am J Health Syst Pharm. 2009 Apr 1;66(7):625-37. doi: 10.2146/ajhp080170.
4
Challenges to integrating pharmacogenetic testing into medication therapy management.
J Manag Care Spec Pharm. 2015 Apr;21(4):346-52. doi: 10.18553/jmcp.2015.21.4.346.
5
Clinical pharmacogenomics: opportunities and challenges at point of care.
Clin Pharmacol Ther. 2013 Jan;93(1):33-5. doi: 10.1038/clpt.2012.196. Epub 2012 Dec 5.
6
The clinical application of UGT1A1 pharmacogenetic testing: gene-environment interactions.
Hum Genomics. 2010 Apr;4(4):238-49. doi: 10.1186/1479-7364-4-4-238.
7
Clinical implementation of pharmacogenetics.
Drug Metab Pers Ther. 2016 Mar;31(1):9-16. doi: 10.1515/dmpt-2015-0031.
8
Expanding role of pharmacogenomics in the management of cardiovascular disorders.
Am J Cardiovasc Drugs. 2013 Jun;13(3):151-62. doi: 10.1007/s40256-013-0024-5.
9
Personalizing medicine with clinical pharmacogenetics.
Genet Med. 2011 Dec;13(12):987-95. doi: 10.1097/GIM.0b013e318238b38c.
10
Developing pharmacogenetic evidence throughout clinical development.
Clin Pharmacol Ther. 2010 Dec;88(6):867-70. doi: 10.1038/clpt.2010.246. Epub 2010 Oct 27.
引用本文的文献
1
Applying Next-Generation Sequencing Platforms for Pharmacogenomic Testing in Clinical Practice.
Front Pharmacol. 2021 Aug 25;12:693453. doi: 10.3389/fphar.2021.693453. eCollection 2021.
2
Pharmacogenetics: An Important Part of Drug Development with A Focus on Its Application.
Int J Biomed Investig. 2018;1(2). doi: 10.31531/2581-4745.1000111. Epub 2018 May 27.
3
The Routine Clinical use of Pharmacogenetic Tests: What it Will Require?
Pharm Res. 2017 Aug;34(8):1544-1550. doi: 10.1007/s11095-017-2128-0. Epub 2017 Feb 24.
4
Challenges of development and implementation of point of care pharmacogenetic testing.
Expert Rev Mol Diagn. 2016 Sep;16(9):949-60. doi: 10.1080/14737159.2016.1211934. Epub 2016 Jul 22.
5
Pilot study of pharmacist-assisted delivery of pharmacogenetic testing in a primary care setting.
Pharmacogenomics. 2014 Sep;15(13):1677-86. doi: 10.2217/pgs.14.109.
6
Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.
Pharmacogenomics. 2013 Jun;14(8):957-68. doi: 10.2217/pgs.13.76.
7
Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.
Neuropsychopharmacology. 2012 Feb;37(3):641-50. doi: 10.1038/npp.2011.232. Epub 2011 Nov 2.
8
Analysis of pharmacogenetic traits in two distinct South African populations.
Hum Genomics. 2011 May;5(4):265-82. doi: 10.1186/1479-7364-5-4-265.
9
Personalized medicine: Striding from genes to medicines.
Perspect Clin Res. 2010 Oct;1(4):146-50. doi: 10.4103/2229-3485.71775.
10
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.
Clin Pharmacol Ther. 2011 Mar;89(3):464-7. doi: 10.1038/clpt.2010.279. Epub 2011 Jan 26.
本文引用的文献
1
Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?
Genet Med. 2009 Jan;11(1):15-20. doi: 10.1097/GIM.0b013e31818efd9d.
2
Pharmacogenetics of Gilbert's syndrome.
Pharmacogenomics. 2008 Jun;9(6):703-15. doi: 10.2217/14622416.9.6.703.
3
Delivery of genomic medicine for common chronic adult diseases: a systematic review.
JAMA. 2008 Mar 19;299(11):1320-34. doi: 10.1001/jama.299.11.1320.
4
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.
J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5. doi: 10.1093/jnci/djm115. Epub 2007 Aug 28.
5
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
J Clin Oncol. 2004 Apr 15;22(8):1382-8. doi: 10.1200/JCO.2004.07.173. Epub 2004 Mar 8.
6
Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Cancer Res. 2000 Dec 15;60(24):6921-6.
7
Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?
Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8170-4. doi: 10.1073/pnas.95.14.8170.
Zotero 插件